Efficacy of Chronic Immunotherapy for Myelin Oligodendrocyte Glycoprotein-IgG Disease
| Identifier | 20190319_nanos_sciplatform3_02_slides |
| Title | Efficacy of Chronic Immunotherapy for Myelin Oligodendrocyte Glycoprotein-IgG Disease |
| Creator | John Chen; Collin McClelland; Eric Eggenberger; Alfonso Lopez Chiriboga; Victoria Pelak; Heather Moss; Aubrey Gilbert; Michael Lee; Marie Acierno; Muhammad Bhatti; Jiraporn Jitprapaikulsan; Gregory Van Stavern; Divyanshu Dubey; Andrew McKeon; Jeffrey Bennett; Sean Pittock; Eoin Flanagan; Ore-ofe Adesina; Shannon Beres; Dean Cestari; Gena Heidary; Byron Lam; Veeral Shah; John Fraser |
| Affiliation | (JC) (ALC) (MB) (JJ) (DD) (AM) (SP) (EF) Mayo Clinic, Rochester, Minnesota; (CM) (ML) University of Minnesota, Minneapolis, Minnesota; (EE) Mayo Clinic, Jacksonville, Florida; (VP) University of Colorado Denver School of Medicine, Aurora, Colorado; (HM) The Stanford University Medical Center, Palo Alto, California; (AG) The Permanente Medical Group, Vallejo, California; (MA) Mayo Clinic, Scottsdale, Arizona; (GV) Washington University in St. Louis School of Medicine, St. Louis, Missouri; (JB) University of Colorado School of Medicine, Aurora, Colorado; (OA) McGovern Medical School at the University of Texas at Houston, Houston, Texas; (SB) Stanford University, Palo Alto, California; (DC) Harvard Medical School, Mass Eye & Ear, Boston, Massachusetts; (GH) Boston Children's Hospital, Boston, Massachusetts; (BL) Bascom Palmer Eye Institute, Miami, Florida; (VS) Texas Children's Hospital/Baylor College of Medicine, Houston, Texas; (JF) Western University, London, Ontario, Canada |
| Subject | Demeylinating Disease; Optic Neuropathy; Neuro-Ophth & Systyemic Disease (eg. MS, MG, Thyroid) |
| Description | Myelin oligodendrocyte glycoprotein autoantibody (MOG-IgG) is a recently established serum biomarker of demyelinating disease that is associated with recurrent CNS attacks. The optimal treatment to lower the risk of or prevent relapses is unknown. The goal of this study was to determine the efficacy of chronic immunotherapy in preventing relapse of MOG-IgG-positive demyelinating events. |
| Date | 2019-03 |
| Language | eng |
| Format | application/pdf |
| Format Creation | Microsoft PowerPoint |
| Type | Text |
| Source | 2019 North American Neuro-Ophthalmology Society Annual Meeting |
| Relation is Part of | NANOS 2019: Scientific Platform III |
| Collection | Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/ |
| Publisher | North American Neuro-Ophthalmology Society |
| Holding Institution | Spencer S. Eccles Health Sciences Library, University of Utah |
| Rights Management | Copyright 2019. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright |
| ARK | ark:/87278/s6rr6k1p |
| Setname | ehsl_novel_nam |
| ID | 1455034 |
| Reference URL | https://collections.lib.utah.edu/ark:/87278/s6rr6k1p |